The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Cartesian Therapeutics Inc shares valued at $11,398 were purchased by SPRINGER TIMOTHY A on Mar 18 ’24. At $0.60 per share, SPRINGER TIMOTHY A acquired 19,044 shares. The insider’s holdings grew to 31,073,406 shares worth approximately $552.8 million following the completion of this transaction.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Also, SPRINGER TIMOTHY A purchased 800 shares, netting a total of over 488 in proceeds. Following the buying of shares at $0.61 each, the insider now holds 104,818 shares.
Before that, SPRINGER TIMOTHY A had added 537,500 shares to its account. In a trade valued at $314,545, the Director bought Cartesian Therapeutics Inc shares for $0.59 each. Upon closing the transaction, the insider’s holdings increased to 537,500 shares, worth approximately $552.46 million.
As published in a research note from Oppenheimer on July 02, 2024, Cartesian Therapeutics Inc [RNAC] has been rated down from an Outperform to a Perform. Analysts at Oppenheimer started covering the stock with ‘”an Outperform”‘ outlook in a report released in early June. As of May 24, 2024, Mizuho has initiated its “Buy” rating for RNAC. Earlier on April 23, 2024, H.C. Wainwright resumed its rating. Their recommendation was “a Buy” for RNAC stock.
Analyzing RNAC Stock Performance
During the last five days, there has been a drop of approximately -28.12%. Over the course of the year, Cartesian Therapeutics Inc shares have dropped approximately -13.98%. Shares of the company reached a 52-week high of $41.87 on 06/06/24 and a 52-week low of $11.66 on 04/08/24. A 50-day SMA is recorded $25.90, while a 200-day SMA reached $25.31. Nevertheless, trading volume fell to 0.35 million shares from 48200.0 shares the previous day.
Support And Resistance Levels for Cartesian Therapeutics Inc (RNAC)
According to the 24-hour chart, there is a support level at 16.25, which, if violated, would cause prices to drop to 14.88. In the upper region, resistance lies at 18.57. The next price resistance is at 19.51. RSI (Relative Strength Index) is 36.08 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at -4.52, which suggests the price will decrease in the coming days. Percent R is at 86.19%, indicating bearish price movement. Stochastics%K at buying indicates that the stock is to be held.
